TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28623954

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg SC Q4W
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg SC Q2W
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo Q4W
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo Q2W
Number of subjects: 163
Study: 25543310

Group type: EXPERIMENTAL
Intervention: Liquid very low calorie diet (VLCD)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Normal consistency diet
Number of subjects: 104
Study: 23391342

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Clonidine150 (Bupivacaine 0.5% + 150 μg of clonidine)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Clonidine250 (Bupivacaine 0.5% + 250 μg of clonidine)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Saline 0.9% (Control group)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%, Clonidine150, Clonidine250
Number of subjects: 140
Study: 21185229

Group type: EXPERIMENTAL
Intervention: Four-week exercise training program (two 1-hour supervised sessions and one 30-minute unsupervised home session per week)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Four-week exercise training program
Number of subjects: 34
Study: 19695029

Group type: EXPERIMENTAL
Intervention: Graph-equipped home blood pressure monitor (n=33)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional home blood pressure monitor (n=32)
Number of subjects: 65
Study: 17404138

Group type: COMPARATOR
Intervention: Children with autism
Number of subjects: 11414

Group type: COMPARATOR
Intervention: Children with asthma
Number of subjects: 11414

Group type: EXPERIMENTAL
Intervention: Children with other special health care needs
Number of subjects: 11414
Study: 15840108

Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 308-nm excimer lamp
Number of subjects: 31

Group type: COMPARATOR
Intervention: 311-nm narrowband UVB
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser (accelerated scheme)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 308-nm excimer lamp (accelerated scheme)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser and lamp
Number of subjects: 31
Study: 11986408

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg, twice-weekly subcutaneous injections)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 40

Group type: COMPARATOR
Intervention: Etanercept and Placebo
Number of subjects: 40
Study: 9698964

Group type: EXPERIMENTAL
Intervention: Modified double burst stimulation at 50 mA
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Modified double burst stimulation at 30 mA
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Modified double burst stimulation at 20 mA
Number of subjects: 121
Study: 7619892

Group type: EXPERIMENTAL
Intervention: CGS 13429A (0.1 to 10 mg)
Number of subjects: 0
Study: 2196520

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 mg/kg twice a day
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.5 mg/kg twice a day
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 346161

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 31710012

Group type: EXPERIMENTAL
Intervention: Sealant + Air Abrasion (AB)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flowable Composite + Air Abrasion (AB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sealant
Number of subjects: 30

Group type: COMPARATOR
Intervention: Flowable Composite
Number of subjects: 30
Study: 28550459

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric care (CGC)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Traditional orthopaedic care (OC)
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 397
Study: 25013088

Group type: EXPERIMENTAL
Intervention: Betaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taurine and GPC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DMG and choline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TMAO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Betaine, DMG, and choline
Number of subjects: 0
Study: 24640648

Group type: EXPERIMENTAL
Intervention: Statokinesitherapy with biological feedback
Number of subjects: 0
Study: 21228334

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg orally on days 1-21 every 28 days until progression or as tolerated
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Lenalidomide for DLBCL
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Lenalidomide for MCL
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Lenalidomide for FL-III
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Lenalidomide for TL
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Lenalidomide for all patients
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Lenalidomide for responders
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Lenalidomide for patients achieving CR
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Lenalidomide for responding patients with FL-III or MCL
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Adverse events related to Lenalidomide
Number of subjects: 217
Study: 20098825

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (GCBT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 52
Study: 17030175

Group type: EXPERIMENTAL
Intervention: Oral norfloxacin (400 mg twice daily)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Intravenous ceftriaxone (1 g/day)
Number of subjects: 111
Study: 15358018

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty + abciximab
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Stenting + abciximab
Number of subjects: 2082
Study: 12575375

Group type: EXPERIMENTAL
Intervention: Qidan Tongmai tablet (QDTMT) in Group A (33 cases without HLC)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Qidan Tongmai tablet (QDTMT) in Group B (33 cases with HLC)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group C (31 cases without HLC)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group D (31 cases with HLC)
Number of subjects: 128
Study: 9032179

Group type: EXPERIMENTAL
Intervention: Anesthesia
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Saline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline VD
Number of subjects: 12

Group type: COMPARATOR
Intervention: Anesthesia VD
Number of subjects: 12
Study: 8436744

Group type: EXPERIMENTAL
Intervention: High serum magnesium (> or = 1.9 mEq/liter)
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Low serum magnesium (< or = 1.5 mEq/liter)
Number of subjects: 1068

Group type: COMPARATOR
Intervention: Normal serum magnesium
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Hypomagnesemia
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Hypermagnesemia
Number of subjects: 1068
Study: 3576521

Group type: EXPERIMENTAL
Intervention: Aspirin 10 mg daily for 3 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Aspirin 30 mg daily for 3 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Aspirin 10 mg and 30 mg
Number of subjects: 19
Study: 28467150

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (120 mg via nasogastric tube for 15 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 27225859

Group type: EXPERIMENTAL
Intervention: 0.005 mg/kg glycopyrrolate
Number of subjects: 84

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 84
Study: 24856612

Group type: EXPERIMENTAL
Intervention: Once-daily glargine
Number of subjects: 1017

Group type: COMPARATOR
Intervention: Twice-daily NPH
Number of subjects: 1017
Study: 22747603

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel (CHX-gel) (5.0%)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chlorhexidine/gutta-percha points (CHX-GP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Octenidine gel (OCT-gel) (5.0%)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste (CH)
Number of subjects: 40
Study: 21504570

Group type: EXPERIMENTAL
Intervention: Proposed CPG implementation strategy to reduce cardiovascular risk
Number of subjects: 620

Group type: COMPARATOR
Intervention: Normal dissemination strategy
Number of subjects: 620
Study: 18429761

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 0
Study: 16927283

Group type: EXPERIMENTAL
Intervention: Pegylated interferon-alpha plus ribavirin (treatment for persistent HCV infection)
Number of subjects: 33
Study: 14499675

Group type: EXPERIMENTAL
Intervention: Intravesical instillations of Bacillus Calmette-Guerin (BCG) during a 6-week induction course followed by maintenance courses at 3, 6, 12, 18, 24, 30 and 36 months
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Intravesical instillations of Bacillus Calmette-Guerin (BCG)
Number of subjects: 487
Study: 10994660

Group type: EXPERIMENTAL
Intervention: linopirdine (a novel phenylinodolinone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: global clinical measure
Number of subjects: 0
Study: 9114191

Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pyrimethamine with rash
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pyrimethamine without rash
Number of subjects: 100
Study: 8479129

Group type: EXPERIMENTAL
Intervention: Antioxidant therapy with two ampoules of Omnibionta (vitamins C, E, A, and B complex) diluted in 500 ml physiological sodium chloride, infused intravenously prior to reperfusion onset.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no antioxidant therapy).
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison between therapy and control groups one hour after reperfusion.
Number of subjects: 30
Study: 3310159

Group type: EXPERIMENTAL
Intervention: Theophylline (TH; 234 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Neo-Biphyllin (NB; 600 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (carbachol)
Number of subjects: 10
Study: 29569403

Group type: EXPERIMENTAL
Intervention: Therapeutic Education System
Number of subjects: 507

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 507
Study: 25995322

Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg, three times daily for 12 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 24742755

Group type: EXPERIMENTAL
Intervention: Adaptive and maladaptive emotion regulation strategies during CBT for SAD
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Contextual factor: treatment study phase
Number of subjects: 71
Study: 23319574

Group type: EXPERIMENTAL
Intervention: Pomalidomide (4 mg) on days 1 to 21 (arm 21/28) plus weekly dexamethasone
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Pomalidomide (4 mg) continuously (arm 28/28) plus weekly dexamethasone
Number of subjects: 84
Study: 19961914

Group type: EXPERIMENTAL
Intervention: Chios mastic gum 350 mg three times daily
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 17340612

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 17153881

Group type: EXPERIMENTAL
Intervention: Beta-glucuronidase (BG) treatment
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 125
Study: 15206735

Group type: EXPERIMENTAL
Intervention: Tryptophan (1 g after each meal for 12 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (for 12 days)
Number of subjects: 100
Study: 10339997

Group type: EXPERIMENTAL
Intervention: Caudal epidural injection of 1 ml (7 mg) bethametason in 10 ml normal saline and 20 ml local anesthetic (Lignocaine 1%)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Caudal epidural injection of 20 ml local anaesthetic (Lignocaine 1%) and 10 ml normal saline
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Superficial injection of 1 ml (7 mg) bethametason around the sacral hiatus
Number of subjects: 39
Study: 7676778

Group type: EXPERIMENTAL
Intervention: 25 mg 0.5% bupivacaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 30 mg 0.5% bupivacaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (25 mg and 30 mg)
Number of subjects: 30
Study: 1773154

Group type: EXPERIMENTAL
Intervention: Co-amoxiclav
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Co-amoxiclav (children < 2 years)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo (children < 2 years)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Co-amoxiclav (children ≥ 2 years)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo (children ≥ 2 years)
Number of subjects: 121
Study: 7353570

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31027084

Group type: EXPERIMENTAL
Intervention: Prolonged anticoagulation therapy (median duration: 72.6 hours)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Brief anticoagulation therapy (median duration: 5 hours)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Prolonged anticoagulation therapy
Number of subjects: 114

Group type: COMPARATOR
Intervention: Brief anticoagulation therapy
Number of subjects: 114
Study: 28110155

Group type: EXPERIMENTAL
Intervention: RO5046013 (PEGylated recombinant human insulin-like growth factor-I)
Number of subjects: 62

Group type: COMPARATOR
Intervention: rhIGF‐I (unmodified recombinant human insulin-like growth factor-I)
Number of subjects: 62
Study: 26499007

Group type: EXPERIMENTAL
Intervention: Drotaverine hydrochloride (20 mg syrup for ages 4-6, 40 mg tablet for ages >6)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 23987516

Group type: EXPERIMENTAL
Intervention: Random-start controlled ovarian stimulation (COS)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conventional-start controlled ovarian stimulation (COS)
Number of subjects: 128
Study: 21932560

Group type: EXPERIMENTAL
Intervention: myocardial cytoprotectors (trimetasidin, mexidol, qudesan)
Number of subjects: 1418
Study: 19621678

Group type: EXPERIMENTAL
Intervention: Combination of two mononucleotide markers (BAT26 and BAT25)
Number of subjects: 1531

Group type: EXPERIMENTAL
Intervention: At least one mononucleotide marker
Number of subjects: 1531

Group type: COMPARATOR
Intervention: Five Bethesda markers
Number of subjects: 1531

Group type: EXPERIMENTAL
Intervention: Two mononucleotide markers
Number of subjects: 1531
Study: 16704591

Group type: EXPERIMENTAL
Intervention: Surgical cricothyroidotomy with a 6.0‐mm cuffed Portex tracheostomy tube
Number of subjects: 27

Group type: COMPARATOR
Intervention: Wire-guided cricothyroidotomy using a 5.0‐mm cuffed Melker tube
Number of subjects: 27

Group type: COMPARATOR
Intervention: Wire-guided cricothyroidotomy using a 6.0‐mm uncuffed Melker tube
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cuffed tubes (Portex and cuffed Melker)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Uncuffed Melker tube
Number of subjects: 27
Study: 15579778

Group type: EXPERIMENTAL
Intervention: Prednisone (0.5 mg/kg.d)
Number of subjects: 6
Study: 11171785

Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy
Number of subjects: 49
Study: 9170767

Group type: EXPERIMENTAL
Intervention: Self-statement questionnaire approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thought-listing procedure
Number of subjects: 0
Study: 8431411

Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery followed by post-operative physical therapy (n = 9)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-surgical treatment (n = 12)
Number of subjects: 21
Study: 3608730

Group type: EXPERIMENTAL
Intervention: Loperamide (16 mg per os)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Loperamide (16 mg per os) followed by naloxone (16 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Loperamide (16 mg per os) followed by naloxone (32 mg)
Number of subjects: 9
Study: 30929605

Group type: EXPERIMENTAL
Intervention: Non-medicated milk replacer (NMR) with sodium butyrate and Bacillus amyloliquefaciens
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pasteurized waste milk (PWM)
Number of subjects: 18
Study: 29310611

Group type: EXPERIMENTAL
Intervention: Oxaliplatin + S-1 (oxaliplatin dose of 130 mg/m2)
Number of subjects: 70
Study: 27608624

Group type: EXPERIMENTAL
Intervention: Home-based self-management training and coaching program (12 weeks, delivered by telephone)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 100
Study: 25622286

Group type: EXPERIMENTAL
Intervention: Positive stereotype activation
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 116
Study: 23265410

Group type: EXPERIMENTAL
Intervention: Increased water and fruit juice consumption during the intervention period.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Increased solid fruit consumption during the control period.
Number of subjects: 70
Study: 21129714

Group type: EXPERIMENTAL
Intervention: Bisoprolol (1.25 mg once daily)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Carvedilol (3.125 mg twice daily)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 320

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 320
Study: 18353086

Group type: EXPERIMENTAL
Intervention: Surface preparation (gentle curettage or abrasion with a spatula)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No surface preparation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 16
Study: 16819684

Group type: EXPERIMENTAL
Intervention: Wrist-bridging external fixation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-bridging external fixation
Number of subjects: 38
Study: 12859442

Group type: EXPERIMENTAL
Intervention: Butterbur (BB) 50 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study: 10394525

Group type: EXPERIMENTAL
Intervention: Psychotherapeutic counseling (PSITCO)
Number of subjects: 1156

Group type: COMPARATOR
Intervention: No psychotherapeutic counseling (PSITCO)
Number of subjects: 1156
Study: 9157078

Group type: EXPERIMENTAL
Intervention: amonafide
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: caracemide
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: homoharringtonine
Number of subjects: 48
Study: 1812440

Group type: EXPERIMENTAL
Intervention: Norwegian meningococcus B vaccine
Number of subjects: 877

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 877
Study: 6822175

Group type: EXPERIMENTAL
Intervention: Protective colostomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Noncolostomy (control group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 31781759

Group type: EXPERIMENTAL
Intervention: Same-day ART (SD ART)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 274
Study: 30178473

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 194
Study: 26731173

Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-delivered acceptance-based behaviour therapy
Number of subjects: 103

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 103
Study: 24875748

Group type: EXPERIMENTAL
Intervention: Complex intervention to support recovery of service users with psychosis
Number of subjects: 28
Study: 22933797

Group type: EXPERIMENTAL
Intervention: Cued recall tested in session 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EEG analysis during cued recall in session 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EEG analysis after 700 ms
Number of subjects: 0
Study: 20505127

Group type: EXPERIMENTAL
Intervention: Triple-pulse stimulation using 120% active motor threshold (AMT) conditioning stimulus (CS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple-pulse stimulation with varying intensities of CS (80-120% AMT) and S2 (120 and 140% AMT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paired-pulse paradigm with CS and S1 followed by S2
Number of subjects: 0
Study: 18568789

Group type: EXPERIMENTAL
Intervention: Dang Gui Buxue Tang
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15747200

Group type: EXPERIMENTAL
Intervention: Schizophrenic persons
Number of subjects: 581

Group type: COMPARATOR
Intervention: Mentally healthy persons
Number of subjects: 581
Study: 11922259

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 135
Study: 9849707

Group type: EXPERIMENTAL
Intervention: Amplitude‐dependent speed of sound (SoS) measurements using DBM Sonic 1200 equipment
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: SoS measurements combined with hip BMD
Number of subjects: 91

Group type: COMPARATOR
Intervention: Hip BMD measurements
Number of subjects: 91
Study: 8085467

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 57
Study: 2529892

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg b.d.
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 100 mg t.d.s.
Number of subjects: 108

Group type: COMPARATOR
Intervention: No active treatment (Control)
Number of subjects: 108